In addition, double-dummy studies are difficult to execute, particularly with regard to dosing compliance.
The patient-eligibility criteria and study design for this phase 3, randomized, double-blind, active-controlled, double-dummy study are described in the primary report by Canon et al (2006) [ 11].
A multicentre, international, randomized, double-blind, double-dummy study was conducted in 504 postmenopausal women ≥55 years of age with a BMD T score of −2.0 and −4.0 who had been receiving alendronate therapy for at least 6 months (in the STAND study).
This can be performed in a blinded double dummy study, which is very difficult to design.
The keywords used to identify the relevant studies were pacifier, dummy, comforter, tooth, malocclusion, deciduous, tongue, swallowing, openbite, crossbite, myofunctional, muscle, and orofacial, and the different terms were combined using Boolean operators.
Those studies were mostly conducted in single panels, without dummies and/or other reactor units.
In multivariable analyses, results were adjusted on all baseline characteristic variables which differed between the two studies, and a dummy variable for study was used to account for additional differing baseline risks between the two cohorts.
A double-blind, double-dummy study design was used to conceal the identity of treatments by use of study drugs and respective matching placebos that were all identical in packaging, labelling, schedule of administration, and appearance.
In a double-blind, double-dummy study, patients were randomly assigned in a 1 1 ratio to receive ticagrelor and placebo (180-mg loading dose followed by 90 mg twice a day) or to receive clopidogrel and placebo (300- to 600-mg loading dose or continuation with a maintenance dose followed by 75 mg per day) for 6 to 12 months.
Methods and Results To evaluate the efficacy of tirofiban in patients undergoing percutaneous revascularization with stent placement, a randomized, multicenter, double-blind, double-dummy, abciximab-controlled study is currently underway.
This double-blind, double-dummy, parallel-group study was designed to show that a pharmacokinetically enhanced formulation of oral amoxycillin clavulanate (16:1, 2000/125 mg), twice daily, is at least as effective clinically and microbiologically as oral amoxycillin clavulanate 1000/125 mg, three times daily, in the 10 day treatment of community-acquired pneumonia (CAP) in adults.
